Startups appoint industry mavens to their board of directors

Obligate, an investment platform enabling companies to issue on-chain bonds and commercial paper to receive funding, has appointed Thomas Zeeb to the company's Board of Directors. Zeeb will bring with him over 30 years of experience in the traditional finance sector, namely in capital markets, securities and exchanges, post-trade infrastructure services, risk management and regulatory compliance. He previously worked at SIX, the Swiss financial services firm where he acted as Global Head of Exchanges, Head of Securities and Exchanges, and CEO of SIX Securities Services. Additionally, Zeeb has been on the company's executive board for 14 years and is chairman of both SIX SIS AG and subsequently SIX Swiss Exchange and SIX Digital Exchange. During his tenure at the firm, Zeeb was responsible for the creation of the SIX Digital Exchange. Today, he also is currently an advisor to Bain Consulting and a board member of Fintica AI, and the Athens Exchange Group.

Crokeo welcomes new chairperson
Raphaël Gindrat, an experienced entrepreneur with an extensive professional network in Switzerland and internationally, is the new Chairman of the Board of Directors of Crokeo, the Swiss start-up pioneering the production and delivery of local food for dogs and cats. Today, more than 1,000 customers receive tailor-made meals for their dogs and cats every month, a figure that continues to climb following the success of Crokeo's recently launched crowdfunding campaign on Wemakeit. Raphaël’a appointment thus comes at a key moment for the start-up, which is about to unveil a range of fresh products never before available on the Swiss market. With significant expertise in strategic development and a solid reputation in the entrepreneurial world. He is co-founder of Bestmile, a pioneering company in the mobility sector, specialising in the management of fleets of autonomous vehicles. As CEO and co-founder, he has steered Bestmile to great heights, with major fundraising and a significant international footprint. Over the course of his career, he has also been associated with renowned institutions such as the World Economic Forum and the Forbes Technology Council.

InterAX appoints a new president of the board
Mark Levick is the former CEO of Alvotech, a global biopharmaceutical company listed on the US NASDAQ is the new president of the board of directors of InterAX Biotech, the ETH Zurich and the Paul Scherrer Institute spinoff pioneering computational pharmacology for creating breakthrough therapies. In addition to building Alvotech’s pipeline, Mark and his team led the approval and commercial launch of Simlandi/Hukyndra in 17 countries. Mark’s expertise was gained through a 25+ year international career leading global research and development groups as Global Head of Development at Sandoz Biopharmaceuticals, Senior Vice President of Global Drug Discovery at Novartis, and Vice-President of biopharmaceutical Translational Medicine at GSK. Before joining the industry, Mark was a medical reviewer for the UK and EU medicines regulatory authorities, and a specialist physician-scientist practising in university hospitals in Australia and the UK. As a researcher at Cambridge University, Mark pioneered the use of reverse genetics to identify novel vaccine targets as well as conducted the earliest in vivo studies using nucleic acid as a novel vaccine platform. Mark has received several awards and authored peer-reviewed papers in the fields of tropical medicine, vaccine immunology and drug development.

Lymphatica Medtech promotes Nanci Govinder to chairperson of the board
Lausanne-based startup Lymphatica Medtech is dedicated to developing new solutions to treat lymphedema using LymphoDrain, an implantable artificial lymphatic discrete wearable device. The company has promoted Nanci Govinder to the role of Chairperson of the Board of Directors. Nancy has been a board member since 2018. The startup also welcomed John Erb as a new Board Member. Previously Chairman of Vascular Solutions Inc. (acquired by Teleflex), and a Board Member of CryoCath Technologies (acquired by Medtronic), Senox Inc. (acquired by CR Bard), and currently Chairman of Nuwellis, Inc, a global medical device company listed on Nasdaq focused on heart failure products, John brings a wealth of experience in developing and marketing vascular products internationally.

(RAN)
Photo L-R: Thomas Zeeb, Raphaël Gindrat, Mark Levick, Nanci Govinder and John Erb